How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,534 results for

Botulinum Toxin Injection

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Injectable Botulinum Toxin for Pelvic Pain: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Injectable Botulinum Toxin for Pelvic Pain: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Injectable Botulinum Toxin for Pelvic Pain: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Injectable Botulinum Toxin for Pelvic Pain: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Injectable Botulinum Toxin for Pelvic Pain: A Review of Clinical Effectiveness, Cost-Effectiveness (...) , and Guidelines Last updated: August 22, 2019 Project Number: RC1170-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of injectable botulinum toxin for pelvic floor pain? What is the cost-effectiveness of injectable botulinum toxin for pelvic floor pain? What are the evidence-based guidelines regarding injectable botulinum toxin for pelvic floor pain? Key Message Two systematic reviews and three randomized

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Toxins for Health? Botulinum toxin for migraine

for Health? Botulinum toxin for migraine. Clinical Question: What is the efficacy of botulinum toxin for migraine prophylaxis? Bottom Line: Patients with chronic migraine who receive botulinum toxin (example Botox™) have 2 fewer migraine days per month compared to placebo (from 19 days to 11 days with treatment versus 13 days with placebo), with no benefit in episodic migraine. Adverse events include blepharoptosis, muscle weakness, neck/injection site pain and 3% stop treatment due to adverse events (...) Toxins for Health? Botulinum toxin for migraine Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca May 13, 2019 Toxins

2019 Tools for Practice

3. Botulinum toxin treatment of spasticity targeted to muscle endplates: an international, randomised, evaluator-blinded study comparing two different botulinum toxin injection strategies for the treatment of upper limb spasticity. Full Text available with Trip Pro

Botulinum toxin treatment of spasticity targeted to muscle endplates: an international, randomised, evaluator-blinded study comparing two different botulinum toxin injection strategies for the treatment of upper limb spasticity. The therapeutic effects of botulinum neurotoxin (BoNT) are well documented in upper limb spasticity. However, several factors may influence treatment efficacy, including targeting of neuromuscular junctions (NMJs). We examined whether NMJ-targeted BoNT injections were (...) non-inferior, in terms of efficacy, to current injection practices.Open-label prospective evaluator-blinded study.Conducted across 20 medical centres in Denmark, Finland, Norway and Sweden (24 September 2012 to 11 March 2015).Aged ˃18 years with upper limb spasticity (Modified Ashworth Scale [MAS] score of 2 or 3) following stroke or traumatic brain injury, had received ≥2 consecutive BoNT-A treatment cycles (the latest of which was abobotulinumtoxinA [aboBoNT-A]) and needed BoNT-A retreatment

2019 BMJ open Controlled trial quality: predicted high

4. C-Arm Guided Percutaneous Radiofrequency Thoracic Sympathectomy for Treatment of Primary Palmar Hyperhidrosis in Comparison with Local Botulinum Toxin Type A Injection, Randomized Trial

C-Arm Guided Percutaneous Radiofrequency Thoracic Sympathectomy for Treatment of Primary Palmar Hyperhidrosis in Comparison with Local Botulinum Toxin Type A Injection, Randomized Trial C-Arm Guided Percutaneous Radiofrequency Thoracic Sympathectomy for Treatment of Primary Palmar Hyperhidrosis in Comparison With Local Botulinum Toxin Type A Injection, Randomized Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features (...) : Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Pain Physician Actions . 2019 Nov;22(6):591-599. C-Arm Guided Percutaneous Radiofrequency Thoracic Sympathectomy for Treatment of Primary Palmar Hyperhidrosis in Comparison With Local Botulinum Toxin Type A Injection, Randomized Trial , , , , Affiliations Expand Affiliations 1 Anesthesia

2020 EvidenceUpdates

5. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Full Text available with Trip Pro

no difference between the two types of botulinum toxin in terms of overall efficacy, with a mean difference of -1.44 (95% CI -3.58 to 0.70) points lower on the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) for BtB-treated participants, measured at two to four weeks after injection. The proportion of participants with adverse events was also not different between BtA and BtB (BtB versus BtA risk ratio (RR) 1.40; 95% CI 1.00 to 1.96). However, when compared to BtA, treatment with BtB (...) Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. This is an update of a Cochrane review first published in 2003. Cervical dystonia is the most common form of focal dystonia and is a disabling disorder characterised by painful involuntary head posturing. There are two available formulations of botulinum toxin, with botulinum toxin type A (BtA) usually considered the first line therapy for this condition. Botulinum toxin type B (BtB) is an alternative option

2016 Cochrane

6. Transurethral Injection of Botulinum Toxin (Botox) into the Bladder Wall for Urinary Incontinence due to Idiopathic Overactive Bladder

Transurethral Injection of Botulinum Toxin (Botox) into the Bladder Wall for Urinary Incontinence due to Idiopathic Overactive Bladder Appli (BO Spons Date o 1. P On 5 Ap of the p incontin Austral Pharma (PBS) l The pro of the b improve was app urologis admitte 2. B At the A botulinu overact 3. P BOTOX In addit cervical dysphon 4. P The sub type A ication 1 OTOX ® ) i sor/Applica of MSAC m Purpose of pril 2013, a procedure to nence due to ia Pty Ltd. T aceutical Be isting of the oposed proc (...) Final DAP for Application 1272 (February 2013) and the fee for intravesical injection of botulinum toxin type A for urinary incontinence due to neurogenic detrusor overactivity (57th MSAC Meeting minutes, Application 1221). The following MBS item was proposed: Applicant proposed wording and fee for the requested MBS item Group T11 – Botulinum toxin Division 2.42A of the General Medical Services Table MBS item no: TBA (within Group T11) BOTULINUM TOXIN (Botox), intravesical injection

2013 Medical Services Advisory Committee

7. Injection of Botulinum Toxin (Botox) for Prophylaxis of Headaches in Adults with Chronic Migraine

Injection of Botulinum Toxin (Botox) for Prophylaxis of Headaches in Adults with Chronic Migraine 1/5 Public Summary Document Application No. 1168 – Botulinum toxin type A for the prophylaxis of headaches in patients with chronic migraine Sponsor/Applicant/s: Allergan Australia Pty Ltd Date of MSAC consideration: 1 August 2013 1. Purpose of application In February 2011, an application to the Medical Services Advisory Committee (MSAC) was received from Allergan Australia Pty Ltd for injection (...) related to botulinum toxin type A (BOTOX ® ), lyophilised powder 100 units, for prophylaxis of headaches in adults with chronic migraine. The recommended dose is 155 units to 195 units, with injections divided across seven specific head and neck areas, and including fixed-site, fixed-dose injections at 31 sites, totalling 155 units and up to an additional 40 units to eight ‘follow the pain’ sites. The drug is administered using a 30-gauge, 0.5 inch needle as 0.1 mL (5 units) injections per site. BOTOX

2013 Medical Services Advisory Committee

8. Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy. (Abstract)

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy. Cerebral palsy (CP) is the most common cause of physical disabilities in children in high-income countries. Spasticity is the most common motor disturbance in CP. Botulinum toxin type A (BoNT-A) is considered the first-line treatment for focal spasticity in people with CP.To evaluate the effectiveness and safety of BoNT-A compared to other treatments used in the management of lower limb spasticity (...) in children with CP.We searched CENTRAL, PubMed, four other databases, and two trial registers in October 2018. We also searched the reference lists of relevant studies and reviews and contacted experts in the field. We did not apply any date or language restrictions.Randomised controlled trials of children with CP, aged between birth and 19 years, treated with BoNT-A injections in the lower limb muscles compared to other interventions. The primary outcomes were gait analysis and function. The secondary

2019 Cochrane

9. Reply to Comment on Ultrasound Guidance for Botulinum Neurotoxin Chemodenervation Procedures. Toxins 2018, 10, 18—Quintessential Use of Ultrasound Guidance for Botulinum Toxin Injections Full Text available with Trip Pro

Reply to Comment on Ultrasound Guidance for Botulinum Neurotoxin Chemodenervation Procedures. Toxins 2018, 10, 18—Quintessential Use of Ultrasound Guidance for Botulinum Toxin Injections We thank the authors for their detailed letter and salient comments related to our article on Ultrasound Guidance for botulinum toxin (BoNT) injections.[...].

2018 Toxins

10. Botulinum toxin type A (Nuceiva) - vertical frown lines

leaflet or contact your doctor or pharmacist. How does Nuceiva work? The active substance in Nuceiva, botulinum toxin type A, is produced by the bacterium Clostridium botulinum. The toxin reduces the release of acetylcholine, a chemical messenger that causes muscle contraction. When Nuceiva is injected directly into the muscles above and between the eyebrows, it causes the muscles to relax, helping to make the vertical lines less noticeable. What benefits of Nuceiva have been shown in studies? Nuceiva (...) of Nuceiva and why it is authorised in the EU What is Nuceiva and what is it used for? Nuceiva is a medicine used to temporarily improve the appearance of vertical frown lines between the eyebrows. It is used in adults less than 65 years of age who have moderate to severe facial lines and in whom those lines are having a significant psychological impact. Nuceiva contains the active substance botulinum toxin type A. How is Nuceiva used? Nuceiva is given by injection into the muscles in the forehead whose

2019 European Medicines Agency - EPARs

11. Outcomes of Ultrasound-Guided Gastrocnemius Injection With Botulinum Toxin for Chronic Plantar Fasciitis (Abstract)

Outcomes of Ultrasound-Guided Gastrocnemius Injection With Botulinum Toxin for Chronic Plantar Fasciitis The objective of this study was to determine whether the injection of botulinum toxin A (BTA) in the medial head of the gastrocnemius muscle could yield improvements in function and disability in patients with chronic plantar fasciitis with follow-up 12 months after treatment.Thirty-two patients with chronic plantar fasciitis were included in the study and randomly allocated to the BTA (...) and placebo groups. The visual analog scale (VAS) and American Orthopaedic Foot & Ankle Society (AOFAS) scores were used to evaluate pain levels pre- and postinjection as well as function of the foot, respectively. Patients were also asked to rate their treatment satisfaction 1 year after injection. The range of dorsiflexion was measured before and 12 months after the injection.At the 12-month follow-up, the mean VAS decreased from 7.8 to 4 in the placebo group and from 8 to 0.33 in the BTA group

2019 EvidenceUpdates

12. Botulinum toxin for motor and phonic tics in Tourette's syndrome. Full Text available with Trip Pro

of whom had a diagnosis of Tourette's syndrome) completed the study; in total, 21 focal motor tics were treated. Although we considered most bias domains to be at low risk of bias, the study recruited a small number of participants with relatively mild tics and provided limited data for our key outcomes. The effects of botulinum toxin injections on tic frequency, measured by videotape or rated subjectively, and on premonitory urge, are uncertain (very low-quality evidence). The quality of evidence (...) for adverse events following botulinum toxin was very low. Nine people had muscle weakness following the injection, which could have led to unblinding of treatment group assignment. No data were available to evaluate whether botulinum injections led to immunoresistance to botulinum.We are uncertain about botulinum toxin effects in the treatment of focal motor and phonic tics in select cases, as we assessed the quality of the evidence as very low. Additional randomised controlled studies are needed

2018 Cochrane

13. Codependent with PBAC- intravesical injection of botulinum toxin (Botox) into the bladder wall for urinary incontinence due to idiopathic overactive bladder

Codependent with PBAC- intravesical injection of botulinum toxin (Botox) into the bladder wall for urinary incontinence due to idiopathic overactive bladder Codependent with PBAC- intravesical injection of botulinum toxin (Botox) into the bladder wall for urinary incontinence due to idiopathic overactive bladder Codependent with PBAC- intravesical injection of botulinum toxin (Botox) into the bladder wall for urinary incontinence due to idiopathic overactive bladder Medical Services Advisory (...) Committee Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Medical Services Advisory Committee. Codependent with PBAC- intravesical injection of botulinum toxin (Botox) into the bladder wall for urinary incontinence due to idiopathic overactive bladder. Canberra: Medical Services Advisory Committee (MSAC). MSAC application 1272. 2013 Authors' conclusions MSAC supported

2013 Health Technology Assessment (HTA) Database.

14. Does Botulinum Toxin Injection into Masseter Muscles Affect Subcutaneous Thickness? Full Text available with Trip Pro

Does Botulinum Toxin Injection into Masseter Muscles Affect Subcutaneous Thickness? Botulinum toxin (BoNT) is widely used to treat masseter muscle hypertrophy. Changes in the muscle thickness have been found in many studies, but there has been no report on changes in the thickness from the skin surface to the masseter muscle.We aimed to use ultrasonography to measure not only changes in the muscle thickness but also changes in subcutaneous thickness.This study enrolled 20 volunteer patients: 10 (...) were assigned to an experimental group (injected with each side 25 U of botulinum toxin into both masseter muscles) and 10 to a control group (injected with normal saline). The thicknesses were measured before the injection and at 4, 8, and 12 weeks after the injection both at rest and during maximum muscle contraction.The subcutaneous thickness did not differ significantly over time either at rest (P = 0.063) or during maximal contraction (P = 0.392), or between the experimental and control groups

2018 Aesthetic surgery journal

15. Intravesical Botulinum Toxin for Adults with Non-Neurogenic Bladder Conditions: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines

Intravesical Botulinum Toxin for Adults with Non-Neurogenic Bladder Conditions: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Last updated: March 15, 2018 Project Number: RC0972-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of intravesical botulinum toxin injection for adults with non-neurogenic bladder conditions? What is the cost-effectiveness of intravesical botulinum toxin (...) injection for adults with non-neurogenic bladder conditions? What are the evidence-based guidelines informing the use of intravesical botulinum toxin injection for adults with non-neurogenic bladder conditions? Key Message Data from four SRs and three RCTs with relatively high quality found that intravesical onabotulinumtoxinA (onabotA) improved overactive bladder (OAB) and bladder pain syndrome/interstitial cystitis (BPS/IC) symptoms compared to placebo (direct comparison) or various anticholinergics

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

16. Chronic anal fissure: botulinum toxin type A injection

for chronic anal fissure in the UK. It is indicated for the relief of pain associated with chronic anal fissure in adults, but is not licensed for children or young people aged under 18 years. Botulinum toxin type A injection is not licensed for treating chronic anal fissure in the UK. Its use for this indication is off-label because different botulinum toxin type A brands (Azzalure, Bocouture, Botox, Dysport, Vistabel and Xeomin) are licensed to treat other conditions in the UK, including muscle (...) ). Page 4 of 34included in the studies in the Cochrane review was a single injection of 20 units of the Botox brand of botulinum toxin type A. This would give a drug-only cost of approximately £77.50 per patient, assuming wastage. This does not include the cost of administration, which is likely to include general or regional anaesthesia in a hospital operating theatre. About this e About this evidence summary vidence summary 'Evidence summaries: unlicensed or off-label medicines' summarise

2013 National Institute for Health and Clinical Excellence - Advice

17. Injection of botulinum toxin (Botox) for prophylaxis of headaches in adults with chronic migraine

Injection of botulinum toxin (Botox) for prophylaxis of headaches in adults with chronic migraine Injection of botulinum toxin (Botox) for prophylaxis of headaches in adults with chronic migraine Injection of botulinum toxin (Botox) for prophylaxis of headaches in adults with chronic migraine Medical Services Advisory Committee Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Medical Services Advisory Committee. Injection of botulinum toxin (Botox) for prophylaxis of headaches in adults with chronic migraine. Canberra: Medical Services Advisory Committee (MSAC). MSAC application 1168. 2012 Authors' conclusions After considering the strength of the available evidence in relation to the safety, clinical effectiveness and cost-effectiveness of injecting botulinum toxin type A (Botox®) in refractory chronic migraine, MSAC supports its public funding via a new

2012 Health Technology Assessment (HTA) Database.

18. Short-Term Effect of Low-Dose, Electromyography-Guided Botulinum Toxin A Injection in the Treatment of Chronic Lateral Epicondylar Tendinopathy: A Randomized, Double-Blinded Study (Abstract)

Short-Term Effect of Low-Dose, Electromyography-Guided Botulinum Toxin A Injection in the Treatment of Chronic Lateral Epicondylar Tendinopathy: A Randomized, Double-Blinded Study Botulinum toxin A (BoNT-A) is a novel treatment for chronic lateral epicondylar tendinopathy. Preliminary studies have demonstrated promising results; however, confirmation of the effectiveness of BoNT-A treatment and further assessment of its side effects are required. This study investigated the analgesic effects (...) of BoNT-A in the treatment of chronic lateral epicondylar tendinopathy.This was a phase-III, single-center, randomized, double-blinded, placebo-controlled study including 60 patients with chronic lateral epicondylar tendinopathy that had been resistant to treatment for >6 months. Patients received either a 40-IU injection of BoNT-A or saline solution placebo into the extensor carpi radialis brevis (ECRB) muscle, aided by electromyographic (EMG) stimulation. Follow-up was 3 months. The primary

2018 EvidenceUpdates

19. Botulinum toxin A for the management of focal spasticity of the upper limbs associated with stroke in adults

published on 16 October 2017 Guidance Recommendation The Ministry of Health's Drug Advisory Committee has recommended: Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials for the management of focal spasticity of the upper limbs associated with stroke in adults who: have a score of 2 or more on the Modified Ashworth Scale at the target muscle intended for botulinum toxin A treatment, do not have the affected joint permanently fixed in position due to fibrotic (...) shortening of the target muscle, and are concurrently receiving physiotherapy. Botulinum toxin A must be administered by either a neurologist trained in movement disorder or a rehabilitation specialist physician who has undergone training to administer botulinum toxin A. Subsidy status Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication. MAF assistance does

2019 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

20. Botulinum toxin A for focal spasticity of the upper or lower limbs in children with cerebral palsy

September 2019 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has recommended: Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials for treating children, aged 2 years or older, with focal spasticity of the upper or lower limbs (including dynamic equinus foot deformity) due to cerebral palsy, and who: do not have significant joint contractures, i.e. the affected joint is not permanently fixed in position due to shortening of the target (...) muscle; and are concurrently receiving ongoing supportive therapy, e.g. physiotherapy or occupational therapy. Botulinum toxin type A must be administered by a physician specialising in paediatric neurological disorders or paediatric rehabilitation with experience in administering botulinum toxin type A. Subsidy status Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials are recommended for inclusion on the Medication Assistance Fund (MAF

2019 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>